Effects of the opioid remifentanil on the arrhythmogenicity of epinephrine in halothane-anesthetized dogs.
Opioids may exert a protective effect against ventricular arrhythmias via a vagally mediated mechanism. This study evaluated the effects of the opioid remifentanil on arrhythmogenicity of epinephrine during halothane anesthesia. Eight dogs were assigned to 2 treatments in a randomized crossover design, with 1-week intervals between treatments. Anesthesia was maintained with 1.3% end-tidal halothane in oxygen and mechanical ventilation to maintain eucapnia. A constant rate infusion of remifentanil (0.72 microg/kg/min) was administered throughout the study in the experimental treatment, while control animals received physiologic saline as placebo. The arrhythmogenic dose of epinephrine (ADE), defined as 4 premature ventricular complexes (PVCs) within 15 s, was determined by administering progressively increasing infusion rates of epinephrine (2.5, 5.0, and 10 microg/kg/min), allowing 20 min intervals between each infusion rate. In both treatments, epinephrine infusions induced bradyarrhythmias and atrioventricular conduction disturbances, which were followed by escape beats and PVCs. In the remifentanil treatment, mean +/- s ADE values (11.3 +/- 4.9 microg/kg) did not differ from values observed in control animals (9.9 +/- 6.1 microg/kg). On the basis of the ADE model for assessing the arrhythmogenity of drugs during halothane anesthesia, the present study did not demonstrate a protective effect of remifentanil (0.72 microg/kg/min) against ventricular arrhythmias in dogs.
Garofalo
Natache A
NA
Department of Veterinary Surgery and Anesthesiology, Faculdade de Medicina Veterinária e Zootecnia, Universidade Estadual Paulista, Botucatu, São Paulo, CEP 18618-000, Brazil.
Teixeira-Neto
Francisco J
FJ
Schwartz
Denise S
DS
Vailati
Maria do Carmo F
Mdo C
Steagall
Paulo V M
PV
D000701:Analgesics, Opioid / Q000494:pharmacology*; D000758:Anesthesia / Q000662:veterinary; D018685:Anesthetics, Inhalation / Q000008:administration & dosage / Q000009:adverse effects*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy / Q000662:veterinary*; D018592:Cross-Over Studies; D004283:Dog Diseases / Q000139:chemically induced / Q000188:drug therapy*; D004285:Dogs; D004562:Electrocardiography / Q000662:veterinary; D004837:Epinephrine / Q000008:administration & dosage; D005260:Female; D006221:Halothane / Q000008:administration & dosage / Q000009:adverse effects*; D006339:Heart Rate / Q000187:drug effects; D007263:Infusions, Parenteral / Q000662:veterinary; D010880:Piperidines / Q000494:pharmacology*; D011897:Random Allocation; D000077208:Remifentanil
D000701:Analgesics, Opioid; D018685:Anesthetics, Inhalation; D000889:Anti-Arrhythmia Agents; D010880:Piperidines; D000077208:Remifentanil; D006221:Halothane; D004837:Epinephrine
Am J Physiol. 1976 Jun;230(6):1469-73
59552
Lab Anim Sci. 1987 Oct;37(5):587-95
3320515
Anesthesiology. 1971 Jul;35(1):48-53
4397352
Am Heart J. 1988 Mar;115(3):598-605
3278576
J Am Vet Med Assoc. 1994 Dec 15;205(12):1679-84
7744639
Cardiovasc Res. 1978 Mar;12(3):167-72
647721
Can J Vet Res. 1997 Jul;61(3):221-6
9243003
Am J Vet Res. 1993 Dec;54(12):2139-44
7906930
Can J Vet Res. 1997 Oct;61(4):241-5
9342445
J Pharmacol Exp Ther. 1997 Apr;281(1):226-32
9103501
Am Heart J. 1978 Feb;95(2):197-203
74946
Anesthesiology. 1996 Apr;84(4):865-72
8638841
Vet Surg. 1994 Jan-Feb;23(1):61-6
8140741
Can J Vet Res. 2001 Apr;65(2):116-24
11346256
Anesth Analg. 1983 Feb;62(2):129-34
6829912
Can J Physiol Pharmacol. 1989 Jul;67(7):801-9
2766111
Clin Exp Pharmacol Physiol. 1993 Feb;20(2):95-102
8383026
Am J Vet Res. 1993 Dec;54(12):2132-8
7906929
Anesth Analg. 1999 Oct;89(4 Suppl):7
10511072
Anesthesiology. 1970 Aug;33(2):193-213
4916273
Can J Vet Res. 1994 Oct;58(4):248-53
7889455